Credit Card Icon
Online bill pay
Calendar Icon
Book Now
Filed Paper Icon
patient portal
Doctor Icon
For Physicians
Phone Icon
(763) 416-7600

Understanding Central Retinal Vein Occlusion: Causes and Symptoms

Posted by: Northwest Eye in central retinal vein occlusion on August 29, 2025

Act quickly when vision changes

CRVO most often causes painless blurring or vision loss in one eye. The change may begin suddenly or develop over several hours or days.

Sudden painless vision loss can have several urgent causes, including a retinal vascular blockage, retinal detachment, bleeding inside the eye, or ischemic optic neuropathy. Symptoms alone cannot show whether the cause is CRVO, so do not wait for the vision change to become painful before seeking qualified eye care.

Understand what CRVO does to the eye

Central retinal vein occlusion happens when the main vein draining blood from the retina becomes partly or completely blocked. A blocked vein can let blood and fluid collect in the retina. When fluid swells the macula, the central area used for detailed vision, central vision may become blurry.

Macular edema means swelling in the macula. This swelling is a common reason for blurred, distorted, or reduced central vision after a retinal vein blockage. The amount of swelling and the amount of blood-flow loss are findings that an eye-care professional measures during evaluation.

About 30% of people with CRVO develop abnormal blood vessels on the iris or retina. These vessels can bleed or raise eye pressure, causing further vision loss. The vessels may also lead to a painful pressure problem called neovascular glaucoma, which is why follow-up remains important after the first diagnosis.

The exact cause of CRVO is often unknown. One estimate places vein occlusion in the second eye at 6% to 17% of CRVO cases, while another estimate finds that nonischemic CRVO makes up about 80% of CRVO cases. These group estimates cannot determine your personal risk or tell you which type you have.

Infographic on CRVO-related retinal findings showing about 30% of people developing abnormal vessels, 6-17% of cases involving second-eye vein occlusion, and about 80% of cases being nonischemic.
These estimates describe CRVO groups, not an individual diagnosis.

Know the two CRVO types

Doctors describe CRVO as nonischemic or ischemic based on how much retinal blood flow is lost. Nonischemic CRVO involves leaky retinal vessels and macular swelling, while ischemic CRVO involves closed-off small retinal blood vessels. Nonischemic CRVO is more common, while ischemic CRVO has a substantially worse visual outlook.

The measure describes a group pattern, not a way to classify your eye without an examination and retinal testing.

CRVO is estimated to affect 2.5 million adults worldwide, with an estimated prevalence of 0.08% to 0.1% among adults worldwide. Prevalence describes the estimated share of that population with the condition; it does not describe the severity of disease or the outlook for one person.

Large clinical trials commonly used monthly anti-VEGF injections for 6 months, followed by monthly injections as needed for CRVO-related macular swelling. The average was 8.2 to 9.5 injections in the first year in that trial setting. A trial schedule is not a personal treatment plan; the amount of swelling, blood-flow loss, and your response guide follow-up.

The difference between nonischemic and ischemic disease matters because the amount of retinal blood-flow loss affects monitoring and treatment decisions. Imaging can help assess poor blood flow, while the retinal examination can show bleeding, swelling, or abnormal new vessels. Your clinician combines these findings rather than relying on one symptom.

Review the risks and possible causes

CRVO usually occurs in people aged 50 and older. It is more common in people with high blood pressure, arteriosclerosis, or diabetes. Other associated risks include high cholesterol, smoking, cardiovascular disease, and blood-clotting disorders. Retinal vein occlusion has also been associated with metabolic syndrome, stroke, and blood hyperviscosity, meaning blood that is unusually thick. These are associations, not a way to diagnose CRVO. A risk factor can shape the health history and examination without identifying the cause of one person’s vision change. Systemic inflammatory conditions such as vasculitis and Behçet disease have also been linked with retinal vein occlusion.

The exact cause of CRVO is often unknown, but a blood clot or reduced blood flow can affect the central retinal vein. In the cited published studies of retinal vein occlusion, high blood pressure was connected with 48% of cases, high cholesterol with 20% of cases, and diabetes with 5% of cases. These percentages describe associations in those studies, not a cause that can be assigned to you without an evaluation.

A health history helps an eye-care professional look for conditions that may affect blood vessels or eye pressure. That discussion may include blood pressure, diabetes, cholesterol, smoking, cardiovascular disease, glaucoma, and any known clotting disorder. A normal health history does not rule out CRVO because the specific cause remains unknown in many cases. When CRVO affects both eyes at the same time, doctors may look more closely for systemic disease or abnormal clotting. The cited ASRS guidance says testing for abnormal clotting is indicated in that situation. Eye doctors often refer patients to a primary-care doctor, internist, or hematologist for the testing.

Risk factors change how an eye-care professional thinks about the evaluation, but they do not establish a diagnosis. Do not assume that having one risk factor means you have CRVO, or that having none means a retinal vein blockage is impossible. Vision changes still need assessment based on their timing and severity. There is no routine screening test for retinal vein occlusion. New blurred vision, distortion, or floaters are the reason to arrange a prompt dilated eye examination.

Bar chart of factors associated with retinal vein occlusion. It shows 48% connected with high blood pressure, 20% with high cholesterol, and 5% with diabetes.
High blood pressure had the largest reported association in these studies.

Recognize how CRVO may look and feel

Vision changes from CRVO may include several patterns:

  • Blurred central vision from macular swelling.
  • Distorted vision, in which straight or familiar details may look altered.
  • Vision that comes and goes, also called a transient visual obscuration.
  • Vision loss affecting part or all of the affected eye.

These patterns can overlap, so the symptom pattern alone cannot identify the type of retinal blockage.

Severe CRVO with complications such as glaucoma may cause eye pain, redness, and irritation. If those symptoms occur with vision loss, use the same-day guidance in the dedicated urgency section rather than trying to identify the cause at home.

A change that develops over hours or days still deserves prompt attention, even if it is mild or fluctuates. Painless symptoms are not a reason to wait. Record whether the change is steady, worsening, or intermittent so you can describe it accurately during the examination.

Expect an eye examination and retinal imaging

Doctors usually diagnose CRVO from your symptoms and eye findings, including a characteristic pattern of retinal bleeding. The examination also helps distinguish CRVO from other conditions that can cause sudden or worsening vision changes. A symptom such as blurred vision is a reason for evaluation, not proof of one diagnosis. CRVO can resemble diabetic retinopathy or retinopathy related to low blood counts. A retina specialist uses the retinal pattern and other findings to help separate these conditions.

An eye evaluation may check your medical history, visual acuity, color vision, pupils, visual fields, eye pressure, and retina through a dilated or fundus examination. Follow-up evaluations may repeat visual acuity, visual-field testing, and retinal examinations so changes can be compared over time. Comparing these results can show whether vision, swelling, or retinal findings are changing, even when your day-to-day symptoms seem similar. Visual acuity describes how clearly you see, while retinal imaging shows physical changes at the back of the eye. The two kinds of information answer different questions during follow-up.

A natural-history study of eyes first seen within 3 months found visual acuity of 20/100 or better in 78% of eyes with nonischemic CRVO and 1% of eyes with ischemic CRVO. After macular edema resolved, visual acuity was 20/100 or better in 83% of nonischemic CRVO eyes and 12% of ischemic CRVO eyes in that study. The percentages describe the study groups and do not predict an individual result.

The examination may also help determine whether swelling, retinal bleeding, reduced blood flow, or abnormal blood vessels are present. Those findings give the clinician a clearer basis for discussing the subtype, treatment choices, and follow-up interval. Ask what each finding means for the next step in your care. Fundus photographs can show retinal bleeding, enlarged or twisted veins, macular changes, and visible abnormal new blood vessels. Fundus photographs also provide a baseline for comparing changes over time.

Bar chart showing eyes with visual acuity of 20/100 or better by CRVO type and study point: 78% nonischemic and 1% ischemic when first seen within 3 months; 83% nonischemic and 12% ischemic after macular edema resolved.
The study reported substantially different visual acuity outcomes by CRVO type.

See what the scans are looking for

Optical coherence tomography, or OCT, is a scan that can show macular edema, fluid, and structural retinal damage. Clinicians use OCT for baseline diagnosis, to monitor macular swelling, and to check treatment response. OCT can also show intraretinal cysts, fluid beneath the retina, retinal thickness, and structural damage. These details help clinicians compare the eye with earlier images and judge whether swelling or other retinal changes are changing. The scan gives information about retinal structure and thickness that cannot be judged from symptoms alone.

Fluorescein angiography uses dye injected into the arm and photographs of the retina to assess blood flow and macular swelling. The findings can help clinicians plan treatment. Because this test uses an intravenous dye, your care team can explain how it will be performed and why it is being considered. Fluorescein angiography requires an injection, and its short image-capture window can limit what the photographs show. Retinal hemorrhage can also block the view.

OCT angiography is a noninvasive scan that does not require dye injection. It can help evaluate areas with poor capillary blood flow and distinguish ischemic from nonischemic CRVO. The scan provides information about blood flow in retinal capillary layers, while OCT focuses more on retinal structure and swelling.

Retinal imaging does not replace the eye examination. Clinicians choose among OCT, fluorescein angiography, and OCT angiography based on the findings they need to clarify, such as swelling, leakage, poor blood flow, ischemia, or abnormal new blood vessels. You can ask which concern each scan is intended to answer.

Match treatment to the eye problem

Treatment for CRVO depends on which problem is affecting the eye. Anti-VEGF injections are widely used to treat macular swelling from retinal vein occlusion. Common anti-VEGF options include aflibercept, bevacizumab, and ranibizumab. They target VEGF to reduce swelling, but they are not a cure. Repeat injections are often needed because the effect wears off.

Steroids can also be used to treat macular swelling caused by CRVO. In a review of 17 randomized controlled trials involving 4,272 eyes, anti-VEGF therapy showed a pooled average difference of 15.14 letters on a standardized ETDRS vision score and reduced central retinal thickness by an average of 350 micrometers. These results describe the treatment groups in that review, not a guaranteed change in your vision.

Panretinal photocoagulation may be used when abnormal new blood vessels develop. The laser can help protect against bleeding and painful pressure increases from neovascular glaucoma, but it does not treat macular swelling. Laser treatment therefore addresses abnormal new vessels rather than the swelling that causes central blurring. For ischemic CRVO with abnormal new blood vessels, anti-VEGF injections can control the vessels promptly but often temporarily. Laser treatment tends to have a more permanent effect, and some people receive both treatments.

The purpose of treatment should be clear before you begin. Anti-VEGF injections or steroids address macular swelling, while panretinal photocoagulation addresses abnormal new blood vessels and helps prevent neovascular glaucoma. A treatment that targets one problem does not necessarily treat the others, so ask which finding the proposed treatment is meant to address.

Treatment often involves monitoring as well as procedures. Your clinician may compare vision, retinal thickness, blood flow, eye pressure, and the presence of abnormal vessels over time. Those comparisons help determine whether treatment should continue, repeat, or change. Real-world results may differ from clinical trials. One study found lower injection frequency and poorer visual outcomes than trials using monthly injections. Clinical-trial schedules therefore describe a study setting, not a guaranteed routine schedule or personal outcome.

Infographic on measured anti-VEGF treatment effects showing a pooled 15.14-letter ETDRS vision difference, 350 micrometers reduced central retinal thickness, 17 randomized controlled trials, and 4272 eyes.
The review summarized effects across 17 trials involving 4272 eyes.

Understand why follow-up matters

Nonischemic CRVO can worsen and become ischemic. An American Society of Retina Specialists patient fact sheet recommends initially scheduled monthly checkups after diagnosis. These visits can look for changes in vision, swelling, retinal blood flow, eye pressure, or abnormal new blood vessels.

Ischemic CRVO can cause abnormal new blood vessels, increased eye pressure, glaucoma, and bleeding in the back of the eye. Follow-up timing is based on vision, swelling, ischemia, eye pressure, and abnormal new blood vessels.

Your follow-up plan may change as the eye changes. Keep the appointments recommended by your eye-care professional, even if your vision seems stable between visits. Report marked or worsening vision loss rather than waiting for the next scheduled appointment.

Monitoring is also how clinicians look for complications that you may not notice right away. Swelling, reduced blood flow, abnormal vessels, and rising eye pressure can require different responses. Ask which findings are being monitored and what change should prompt an earlier evaluation. Clinicians also examine the iris, drainage angle, retina, and optic disc and check eye pressure when abnormal new blood vessels are suspected. This examination looks for changes that may not be visible to you, including vessels in the front of the eye that can interfere with fluid drainage and raise pressure.

Know when to seek same-day help

Sudden vision loss needs immediate evaluation, even when it is not painful. Seek prompt retina assessment for marked or worsening vision loss, suspected ischemic CRVO, extensive blood-flow loss, vision-threatening macular edema, bleeding inside the eye, or suspected abnormal new blood vessels.

Get same-day or emergency evaluation for any of the following:

  • Painful vision loss.
  • Very high eye pressure.
  • A red eye with nausea or headache.

Do not delay evaluation while trying to decide whether the vision change is CRVO. Symptoms alone cannot establish the cause.

Urgency does not depend only on pain. A painless change can still come from a vision-threatening retinal condition, and worsening vision may signal a need for prompt retina assessment. Use the timing and severity of the change to guide your next action, not the absence of discomfort.

Arrange the right next evaluation

New or worsening vision changes deserve qualified eye evaluation, even when there is no pain. At Northwest Eye, we invite you to discuss those changes and the appropriate next steps at our Minnetonka location. Bring the timing of the change and any related symptoms to the visit so the examination can address the most relevant concerns. A qualified eye-care professional must decide what your examination findings mean and which treatment suits your eye.

Questions to ask about CRVO evaluation and treatment

What should I do if I have sudden, painless vision loss and worry about central retinal vein occlusion?

Seek immediate qualified eye evaluation, even if the vision change is painless. Symptoms alone cannot show whether the cause is CRVO, retinal detachment, bleeding inside the eye, or another urgent condition. Note when the change began, whether one or both eyes are affected, and any pain, flashes, floaters, headache, or jaw pain.

Can symptoms tell me whether CRVO is ischemic or nonischemic?

No. Blurred or distorted vision can occur with either type, and symptoms alone cannot measure retinal blood-flow loss. Clinicians use the eye examination and retinal imaging to assess swelling, bleeding, ischemia, eye pressure, and abnormal blood vessels. Ischemic disease is more severe and generally has a worse visual outlook, so evaluation should not be delayed.

What tests might an eye doctor use to check for CRVO?

An evaluation may include visual acuity, color vision, pupil and visual-field checks, eye-pressure measurement, and a dilated retinal examination. OCT can show macular swelling and structural damage. Fluorescein angiography uses injected dye to assess leakage and blood flow, while OCT angiography does not require dye and can help assess poor capillary blood flow.

When does a CRVO complication require same-day or emergency evaluation?

Get same-day or emergency evaluation for painful vision loss, very high eye pressure, or a red eye with nausea or headache. Marked or worsening vision loss, suspected ischemic disease, bleeding inside the eye, vision-threatening macular swelling, or suspected abnormal new blood vessels also require prompt retina assessment rather than waiting for a routine appointment.


locations

Serving Our Community

With six locations throughout the Twin Cities metro area, Northwest Eye is among the largest eye care providers in the Midwest. Be Eye Wise and schedule a general eye exam or a specific service consultation today. We have optical  at the following offices:  Golden Valley, Minnetonka, Maple Grove, St. Anthony, and Wayzata, MN.

8501 Golden Valley Rd.,
Suite 100 & 200
Golden Valley, MN 55427
Additional Golden Valley Information
12501 Whitewater Drive, Suite 110
Minnetonka, MN 55343
Additional Minnetonka Clinic (Crosstown) Information
12000 Elm Creek Blvd N., Suite 100
Maple Grove, MN 55369
Additional Maple Grove Information
2601 39th Ave NE., Suite 1
St. Anthony, MN 55421
Additional St. Anthony Information
1903 E. Wayzata Blvd., Suite 110
Wayzata, MN 55391

Additional Wayzata Information
7125 Tamarack Rd, Suite 150,
Woodbury, MN 55125
Additional Woodbury Information
11091 Ulysses St NE., Suite 400
Blaine, MN 55434
Additional Blaine Surgery Center Information
9801 Dupont Ave S., Suite 100
Bloomington, MN 55431
Additional Bloomington Surgery Center Information
12501 Whitewater Drive
Suite 320
Minnetonka, MN 55343
Additional Crosstown Surgery Center Information
10709 Wayzata Blvd., Suites 100 & 120
Minnetonka, MN 55305
Additional Minnetonka Surgery Center Information